Atomoxet
3.9 (5 customer reviews)Taken by mouth as an individualized daily treatment, Atomoxet contains atomoxetine for attention-deficit/hyperactivity disorder (ADHD). It is used in children, adolescents, and adults to support sustained attention and reduce impulsive or hyperactive behavior. Atomoxetine works by increasing norepinephrine signaling in brain areas involved in focus and self-regulation.
Overview
Atomoxet is a non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder. Its active substance, atomoxetine hydrochloride, belongs to the selective norepinephrine reuptake inhibitor class. Unlike stimulant ADHD medicines, it does not act by directly increasing dopamine release.
Therapeutic indications
ADHD can involve inattentiveness, disorganization, impulsivity, restlessness, and difficulty completing routine tasks. Atomoxet is prescribed when these symptoms interfere with school, work, relationships, or daily functioning. The FDA recognizes atomoxetine for ADHD treatment in children, adolescents, and adults. [1]
How it affects the body
Atomoxetine blocks the norepinephrine transporter, a protein that normally removes norepinephrine from the space between nerve cells. More norepinephrine remains available to support signaling in the prefrontal cortex, the brain region linked with attention, planning, and impulse control.
This action may reduce impulsivity and hyperactivity while improving the ability to stay with a task. Atomoxetine is not a sedative.
Influence on Neurotransmitters and Cognitive Function
Atomoxetine hydrochloride has a stronger effect on norepinephrine than on dopamine in most parts of the brain. This distinction explains why it is classed as a non-stimulant option for ADHD. Clinical guidelines include atomoxetine among evidence-based pharmacological treatments when stimulants are unsuitable, poorly tolerated, or not preferred. [2]
Reasons not to use it
Atomoxet is contraindicated with:
- monoamine oxidase inhibitors such as phenelzine, tranylcypromine, and moclobemide, or use of one recently;
- narrow-angle glaucoma;
- pheochromocytoma;
- a history of severe hypersensitivity to atomoxetine.
Extra caution is needed with serious cardiovascular disease, uncontrolled high blood pressure, fast heart rhythm, severe liver impairment, bipolar disorder, psychosis, or a history of suicidal thoughts.
Strong CYP2D6 inhibitors, including fluoxetine, paroxetine, and quinidine, require clinical management. Medicines that increase blood pressure or heart rate, other medicines affecting norepinephrine, amphetamines, and viloxazine also require careful clinical oversight.
When this is not for you
Do not use Atomoxet if you take an MAOI, have narrow-angle glaucoma, pheochromocytoma, or have had a severe allergic reaction to atomoxetine. Tell your prescriber before treatment if you have serious heart or blood-pressure problems, liver disease, bipolar disorder, psychosis, or a history of suicidal thoughts. Also discuss fluoxetine, paroxetine, quinidine, medicines that raise blood pressure or heart rate, and other treatments affecting norepinephrine.
Possible side effects
Atomoxetine can cause side effects, especially early in treatment or after a dose increase. Common effects include nausea, dry mouth, reduced appetite, abdominal discomfort, fatigue, dizziness, constipation, headache, and sleep changes. Some people feel sleepy; others feel more alert or find it harder to fall asleep. The severity and duration of these effects vary between patients. A prescriber can assess persistent or troublesome symptoms and adjust the treatment plan when appropriate.
Children and adolescents may experience reduced appetite, stomach upset, tiredness, or mood changes. Adults may also report dry mouth, constipation, sweating, urinary hesitation, or sexual side effects. These reactions do not occur in everyone, and mild symptoms may ease as the body adapts.
More serious reactions need prompt attention. These include chest pain, fainting, a racing or irregular heartbeat, yellowing of the skin or eyes, dark urine, severe abdominal pain, severe agitation, new manic behavior, hallucinations, or suicidal thoughts. The FDA warning information also highlights the need to watch for unusual behavioral changes in children and adolescents. [4]
Formulation
Active Ingredient and Composition
Atomoxet contains atomoxetine hydrochloride. Atomoxetine is the active form that reaches the bloodstream after oral administration and acts on norepinephrine transporters in the central nervous system.
Norepinephrine is a neurotransmitter involved in alertness, planning, working memory, and behavioral inhibition. Atomoxet does not provide an immediate stimulant-like effect. Its benefit develops gradually with regular use.
Dosage and administration
Atomoxet is an oral atomoxetine treatment. The amount per intake is set individually for each person rather than being one fixed number. A prescriber considers age, body weight in younger patients, response, adverse effects, liver function, and medicines that affect atomoxetine metabolism.
The aim is to find a dose that improves ADHD symptoms without creating avoidable adverse effects. Dose adjustments are not a sign that treatment has failed. They are a routine part of atomoxetine therapy.
Common prescribing factors include:
- symptom severity and functional impairment;
- daytime sleepiness or insomnia;
- nausea or reduced appetite during the first weeks;
- high blood pressure, rapid pulse, or heart disease;
- use of medicines that inhibit the CYP2D6 enzyme;
- previous response to stimulant or non-stimulant ADHD treatment.
Atomoxet is taken orally once daily or divided into two daily doses when a clinician considers that schedule more suitable. It may be taken with or without food. Taking it at a similar time each day helps maintain a predictable routine.
The dose is usually started conservatively and adjusted according to benefit and tolerability. Children and adolescents often require weight-informed dosing, while adult dosing is individualized around symptoms and adverse effects. The American Academy of Pediatrics recommends medication management as part of a broader ADHD care plan that can also include behavioral and educational supports. [3]
If a dose is missed, take it when remembered unless it is close to the next scheduled dose. Do not take an extra dose to compensate.
Comparison
Atomoxet gives a non-stimulant route to ADHD symptom control. It may suit people who need steady all-day coverage, have not tolerated stimulants, or have concerns about misuse potential. The trade-off is slower symptom improvement than is typical with stimulant medicines.
Methylphenidate may be chosen when rapid symptom change is needed and stimulants are appropriate. Guanfacine may be useful where sleep problems, tics, or marked hyperactivity are prominent. Atomoxetine is often selected when a gradual, non-stimulant approach fits the clinical picture.
Common mistakes
Several practical errors can make Atomoxet seem less useful or less tolerable than it is.
- Expecting a same-day effect and stopping after only a few doses.
- Taking doses inconsistently, then trying to judge focus from one unusually busy day.
- Doubling a missed dose, which can increase adverse effects.
- Ignoring a sustained rise in pulse, blood pressure, severe mood change, or liver-related symptoms.
- Starting fluoxetine, paroxetine, or another interacting medicine without reviewing atomoxetine therapy.
- Assuming reduced appetite is harmless when food intake or weight is falling over time.
- Using large amounts of caffeine to overcome tiredness, then attributing palpitations or insomnia solely to Atomoxet.
What doctors say
In clinical practice, atomoxetine is often viewed as a steady, long-range ADHD treatment rather than a quick performance enhancer. Clinicians usually look for progress in daily function: completing assignments, driving more safely, interrupting less, keeping routines, and recovering from distractions faster.
Doctors also watch the first phase closely. Sleep, appetite, mood, blood pressure, and pulse can reveal whether the schedule or dose needs adjustment. A person may notice modest behavioral changes before they feel a dramatic improvement in concentration.
Consistency matters because atomoxetine’s benefit builds over time. If ADHD symptoms remain unchanged after an adequate clinician-guided trial, the treatment plan may need reassessment rather than abrupt self-directed changes.
Common questions
Atomoxet should be kept in a cool, dry environment away from direct light and humidity.
A bedroom drawer or closed cabinet away from heat sources is generally more suitable than a bathroom. During travel, protect the medicine from extreme heat and keep it secured to prevent accidental access by children. The National Library of Medicine's 2024 guidance advises storing atomoxetine at room temperature and away from moisture and heat. [5]
Some antidepressants can change how the body processes atomoxetine.
Fluoxetine and paroxetine are strong CYP2D6 inhibitors and can raise atomoxetine exposure, increasing the chance of side effects such as nausea, dizziness, faster pulse, or sleep disruption. A clinician may need to alter the treatment plan when these medicines are used together. The FDA prescribing information from 2022 addresses this interaction and the need for individualized management.
Atomoxetine can cause sexual side effects in some adults, including erectile dysfunction, delayed ejaculation, reduced libido, or urinary hesitation.
These effects are not universal, and people may be reluctant to mention them unless asked directly. They can be related to norepinephrine activity and may improve after a clinician-guided adjustment. FDA safety information from 2022 lists sexual adverse effects among reactions reported during treatment.
Stop taking Atomoxet and seek urgent medical care for chest pain, fainting, severe shortness of breath, facial swelling, severe rash, yellow skin or eyes, dark urine, or intense abdominal pain.
New suicidal thoughts, marked aggression, hallucinations, or manic behavior also require urgent clinical contact. These symptoms are uncommon, but they should not be managed by waiting for the next routine appointment. The FDA's 2022 warnings emphasize monitoring behavioral changes, especially early in treatment and during dose changes.
Atomoxet usually works gradually rather than immediately.
Some people notice early changes in organization or impulsivity within the first weeks, while fuller benefit may take longer with regular daily use. A single productive day does not prove the medicine is working, just as one distracted day does not prove it has failed. NICE's 2018 guidance supports reviewing ADHD medication response through day-to-day functional outcomes, not attention alone.
The duration of Atomoxet treatment depends on ADHD symptoms, functional benefit, tolerability, and the wider care plan.
Long-term use can be appropriate when the medicine continues to provide meaningful improvement and monitoring remains satisfactory. Periodic reviews should cover blood pressure, pulse, appetite, mood, sleep, and ongoing need for treatment. The American Academy of Pediatrics guideline from 2019 supports continued ADHD care that is adjusted to the patient’s changing needs across life stages.
Regular sleep, predictable meals, movement, and a realistic planning system can make ADHD treatment easier to evaluate.
Excess caffeine can worsen jitteriness, fast pulse, anxiety, and insomnia, especially during early atomoxetine treatment. Alcohol can impair judgment and make dizziness or mood changes harder to interpret. Behavioral strategies such as written task lists, reminder systems, and structured breaks are consistent with the 2019 American Academy of Pediatrics guideline and work alongside medication rather than competing with it.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in.) and its contents cannot be seen.
Comparison
Prescription Regulation and Storage Guidelines
Keep it in a cool, dry place away from direct sunlight and excessive humidity.
Store Atomoxet out of reach of children and pets. Avoid keeping it in a bathroom cabinet, where repeated heat and moisture can affect medicines over time.
Customer Feedback on Atomoxet
Sources
- Food and Drug Administration (2022). STRATTERA (atomoxetine) capsules, for oral use: Prescribing Information.
- National Institute for Health and Care Excellence (2018). Attention deficit hyperactivity disorder: diagnosis and management (NG87).
- American Academy of Pediatrics (2019). Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
- Food and Drug Administration (2022). Atomoxetine: Medication Guide and Safety Information.
- National Library of Medicine (2024). Atomoxetine: MedlinePlus Drug Information.